Soriani et al. (49) noted that myeloma cells treated with low doses of therapeutic agents (e.g., doxorubicin, melphalan, bortezomib) used commonly in patients with multiple myeloma up-regulated expression of DNAM-1 and NKG2D ligands. The gene discussed is KLRK1; the disease is AL amyloidosis.